Malignant Mixed Neoplasm — Trials

Malignant Mixed Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

348 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 48
Ph III recruiting: 12
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05600491	A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme	unknown	Phase 3	78	Sun Yat-sen UniversityOTHER	1	Oct 31, 2022	clinicaltrials
NCT00108745	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	unknown	Phase 3	1,157	GOG FoundationNETWORK	1	Sep 30, 2021	clinicaltrials